Literature DB >> 31451575

Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".

Eiman M Mokaddas1,2, Suhail Ahmad3, Hanaa S Eldeen2.   

Abstract

Year:  2019        PMID： 31451575      PMCID： PMC6711895          DOI： 10.1128/JCM.00984-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  5 in total

1.  Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence.

Authors:  Eiman Mokaddas; Suhail Ahmad; Hanaa S Eldeen; Noura Al-Mutairi
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

2.  Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.

Authors:  Patrick Murray; Charles Cooper; Courtney Maus
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

3.  GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).

Authors:  E M Mokaddas; S Ahmad; H S Eldeen
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

4.  Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005.

Authors:  E Mokaddas; S Ahmad; I Samir
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

5.  Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.

Authors:  Noura M Al-Mutairi; Suhail Ahmad; Eiman Mokaddas; Hanaa S Eldeen; Susan Joseph
Journal:  BMC Infect Dis       Date:  2019-01-03       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.